Daiichi Sankyo Co Ltd

Daiichi Sankyo’s decision to join Interpharma is a bold move that could impact the pharmaceutical industry, while the Asian market’s rebound is uncertain due to the upcoming US tariff announcements.

Daiichi Sankyo’s market position is expected to strengthen in the coming years due to the growing demand for its oncology treatment, TAGRISSO, driven by the rising prevalence of EGFR mutations and increasing lung cancer diagnoses.